10. Dez. 2019OA Dr. Reinhard Ruckser

ASH 2019: „Das Ziel bei CLL ist die Heilung in der Erstlinie“

OA Dr. Reinhard Ruckser, 2. Medizinische Abteilung, Sozialmedizinisches Zentrum Ost – Donauspital, Wien, erklärt, warum die chemofreie Erstlinie bei CLL für viele Patienten bald Standard sein könnte und gibt einen Überblick über wichtige ASH-Abstracts bei CLL, AML, Multiplem Myelom und Non-Hodgkin-Lymphomen.

Inhalte im Video:
Interview von:
Produziert von:

Quelle: ASH Annual Meeting 2019

Abstracts, die im Video erwähnt werden:

Seymour JF et al., Abstract 355
Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Fischer K et al., Abstract 36
Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Schuster SJ et al., Abstract 6
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Borthakur GM et al., Abstract 290
Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)Clinically Relevant Abstract

Statler A et al., Abstract 16
The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction ChemotherapyClinically Relevant Abstract

Dieser Beitrag erschien auch im Printmagazin krebs:hilfe!